[go: up one dir, main page]

MX2017000141A - Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. - Google Patents

Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.

Info

Publication number
MX2017000141A
MX2017000141A MX2017000141A MX2017000141A MX2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A MX 2017000141 A MX2017000141 A MX 2017000141A
Authority
MX
Mexico
Prior art keywords
making
methods
same
targeted therapeutic
therapeutic nanoparticles
Prior art date
Application number
MX2017000141A
Other languages
English (en)
Inventor
Hong Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017000141A publication Critical patent/MX2017000141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen nanopartículas poliméricas que incluyen un agente terapéutico, y métodos para elaborar y utilizar tales nanopartículas terapéuticas; en algunas modalidades, las nanopartículas contempladas pueden incluir un excipiente.
MX2017000141A 2014-07-03 2015-07-02 Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas. MX2017000141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020609P 2014-07-03 2014-07-03
PCT/US2015/038963 WO2016004290A1 (en) 2014-07-03 2015-07-02 Targeted therapeutic nanoparticles and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2017000141A true MX2017000141A (es) 2017-04-25

Family

ID=53724455

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000141A MX2017000141A (es) 2014-07-03 2015-07-02 Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.

Country Status (12)

Country Link
US (3) US10182996B2 (es)
EP (1) EP3164119B1 (es)
KR (2) KR20190018052A (es)
CN (1) CN107072962A (es)
AU (1) AU2015284017A1 (es)
BR (1) BR112017000022A2 (es)
CA (1) CA2953996A1 (es)
ES (1) ES2847894T3 (es)
IL (1) IL249894A0 (es)
MX (1) MX2017000141A (es)
RU (1) RU2706791C2 (es)
WO (1) WO2016004290A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190099374A1 (en) * 2016-03-25 2019-04-04 Pfizer Inc. Stable formulations for lyophilizing therapeutic particles
US20200054628A1 (en) * 2016-10-20 2020-02-20 Pfizer Inc. Therapeutic Polymeric Nanoparticles Comprising Lipids and Methods of Making and Using Same
WO2018141810A1 (en) * 2017-01-31 2018-08-09 Alf Lamprecht Use of nanoparticles for immunotherapy
US10369230B2 (en) 2017-04-06 2019-08-06 National Guard Health Affairs Sustained release of a therapeutic agent from PLA-PEG-PLA nanoparticles for cancer therapy
CN111107842B (zh) * 2017-09-22 2021-10-08 杭州景杰生物科技股份有限公司 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒
US10704094B1 (en) 2018-11-14 2020-07-07 Element Biosciences, Inc. Multipart reagents having increased avidity for polymerase binding
US12313627B2 (en) 2019-05-01 2025-05-27 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
EP4255495A4 (en) 2020-12-03 2025-10-08 Battelle Memorial Institute COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2024053862A1 (ko) * 2022-09-08 2024-03-14 주식회사 삼양홀딩스 약물 함유 나노입자 제조용 키트 및 약물전달용 나노입자 조성물
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050450A1 (en) * 2006-06-26 2008-02-28 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
CA2665343C (en) * 2006-10-05 2014-12-16 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US20090148384A1 (en) * 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
WO2010005723A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
ES2721850T3 (es) * 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
EP2306829B1 (en) * 2008-07-01 2017-01-04 University of Chicago Particles containing a peripheral opioid receptor antagonist
JP5906181B2 (ja) * 2009-04-24 2016-04-20 イシューティカ ピーティーワイ リミテッド 商業的ナノ粒子及びマイクロ粒子粉末の生産方法
JP5965844B2 (ja) * 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
WO2012101242A1 (en) * 2011-01-27 2012-08-02 Capsulution Pharma Ag Novel pharmaceutical suspension for parenteral application
US20130149381A1 (en) * 2011-12-08 2013-06-13 Centro De Investigacion En Quimica Aplicada Absorption method for entrapment of drugs in polymeric nanoparticles
RU2631599C2 (ru) * 2011-12-14 2017-09-25 Дзе Джонс Хопкинс Юниверсити Наночастицы, легче проникающие в слизистую оболочку или вызывающие меньше воспаления
CA2863632C (en) * 2012-01-19 2017-07-11 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
CN103585634A (zh) * 2013-10-22 2014-02-19 汤民 一种多西他赛聚合物纳米药物制剂及其制备方法

Also Published As

Publication number Publication date
US20190151251A1 (en) 2019-05-23
CA2953996A1 (en) 2016-01-07
US10182996B2 (en) 2019-01-22
BR112017000022A2 (pt) 2017-11-07
ES2847894T3 (es) 2021-08-04
RU2016149734A3 (es) 2018-08-06
RU2016149734A (ru) 2018-08-06
IL249894A0 (en) 2017-03-30
US20200306201A1 (en) 2020-10-01
WO2016004290A1 (en) 2016-01-07
EP3164119B1 (en) 2020-11-18
RU2706791C2 (ru) 2019-11-21
US20170128380A1 (en) 2017-05-11
AU2015284017A1 (en) 2017-01-05
KR20190018052A (ko) 2019-02-20
KR20170023173A (ko) 2017-03-02
EP3164119A1 (en) 2017-05-10
CN107072962A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
IL291922B1 (en) FAP-activated medical materials and related uses
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
PH12016502142A1 (en) Anti-ptk7 antibody-drug conjugates
IL254977B (en) Biological conjugates and their uses
AU362319S (en) Pet treat
GB201512203D0 (en) Agents,uses and methods
GB2541571A (en) Pharmaceutical compositions
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
GB2587284B (en) Well ranging apparatus. methods, and systems
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
GB201512215D0 (en) Agents,uses and methods
AU2015315168A8 (en) Targeted mutagenesis in spirulina
IL271728A (en) Materials, uses and treatment methods
IL248196A0 (en) Polymer template and preparations for it
PH12017500602A1 (en) Methods for treating ocular conditions
AU359166S (en) Earplug
AU359108S (en) Earplug
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
IL250844A0 (en) Medical nanoparticles and related preparations, methods and systems
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
PT3294361T (pt) Um stent ureteral, métodos e utilizações dos mesmos
JO3628B1 (ar) كينازولين مهلجن-thf-أمينات على هيئة مثبطات pde1
AU359167S (en) Earplug
AU356666S (en) Hearing device retainer